This Article Full Text Full Text (PDF) CME: Take the course for this article: Stroke: July 2007, Volume 38, Number 7 All Versions of this Article: 38/7/2196    most recent STROKEAHA.106.480004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arenillas, J. F. Articles by Dávalos, A. Search for Related Content PubMed PubMed Citation Articles by Arenillas, J. F. Articles by Dávalos, A. Related Collections Other Stroke Treatment - Medical

(Stroke. 2007;38:2196.)
© 2007 American Heart Association, Inc.

Emerging Therapies

The Metabolic Syndrome and Stroke

Potential Treatment Approaches

Juan F. Arenillas, MD, PhD; María A. Moro, PhD Antoni Dávalos, MD, PhD

From the Stroke Unit, Department of Neurosciences (J.F.A., A.D.), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain; and the Department of Pharmacology (M.A.M.), School of Medicine, Universidad Complutense, Madrid, Spain.

Correspondence to Antoni Dávalos, MD, PhD, Department of Neurosciences, Hospital Germans Trias i Pujol, Ctra de Canyet s/n, 08916 Badalona, Spain. E-mail adavalos.germanstrias@gencat.net

Marc Fisher MD Kennedy Lees MD Section Editors

Key Words: glitazones • metabolic syndrome • treatment

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The metabolic syndrome (MetS) consists of a constellation of vascular risk factors and metabolic abnormalities comprising (1) centrally distributed obesity; (2) atherogenic dyslipidemia, characterized mainly by elevated triglycerides and decreased high-density lipoproteins; (3) high blood pressure; and (4) hyperglycemia.¹ This cluster of highly interrelated factors appears to increase the individual’s risk of vascular disease by promoting the development of atherosclerotic vascular disease and type II diabetes mellitus.²

It is important to recognize that the MetS is a syndrome and not a defined uniform entity. In the effort to introduce the MetS into clinical practice, diverse organizations have used different diagnostic criteria, which may respond to 2 main different conceptual approaches to the syndrome (Table). The first approach focuses on the pathogenesis of MetS and considers insulin resistance as the common physiological abnormality that can lead to the clustering of the mentioned metabolic risk factors and therefore as a main therapeutic target.^3–5 The second approach responds to a more pragmatic view and has the purpose of identifying people at higher long-term risk for atherosclerotic vascular disease who may deserve clinical intervention to reduce vascular risk.^6,7 These distinct conceptual views of the MetS have probably contributed to a lack of certainty regarding its pathogenesis and value as a cardiovascular disease risk marker.^8,9 Therefore, for now, we will attempt to follow a comprehensive and pathogenesis-based approach to MetS to make our exposition more intelligible.

View this table:   Proposed Criteria for the Diagnosis of the Metabolic Syndrome

	Insulin Resistance: A Proposed Common Underlying Pathophysiological Mechanism

 
Insulin resistance is a metabolic disorder characterized by . . . [Full Text of this Article]

This article has been cited by other articles:

				P. V. G. Katakam, F. Domoki, J. A. Snipes, A. R. Busija, Y. P. R. Jarajapu, and D. W. Busija Impaired mitochondria-dependent vasodilation in cerebral arteries of Zucker obese rats with insulin resistance Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R289 - R298. [Abstract] [Full Text] [PDF]

				J. F. Arenillas, P. Sandoval, N. Perez de la Ossa, M. Millan, C. Guerrero, D. Escudero, L. Dorado, E. Lopez-Cancio, J. Castillo, and A. Davalos The Metabolic Syndrome Is Associated With a Higher Resistance to Intravenous Thrombolysis for Acute Ischemic Stroke in Women Than in Men Stroke, February 1, 2009; 40(2): 344 - 349. [Abstract] [Full Text] [PDF]

				J. F. Arenillas, L. Ispierto, M. Millan, D. Escudero, N. Perez de la Ossa, L. Dorado, C. Guerrero, J. Serena, J. Castillo, and A. Davalos Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke Neurology, July 15, 2008; 71(3): 190 - 195. [Abstract] [Full Text] [PDF]

				T. Kurth and G. Logroscino The Metabolic Syndrome: More Than the Sum of Its Components? Stroke, April 1, 2008; 39(4): 1068 - 1069. [Full Text] [PDF]